Lexeo Therapeutics (LXEO) Operating Leases (2022 - 2026)

Lexeo Therapeutics' Operating Leases history runs 5 years deep, the most recent figure standing at $4.5 million for Q1 2026.

• In Q1 2026, Operating Leases fell 26.13% year-over-year to $4.5 million; the TTM figure through Mar 2026 stood at $4.5 million (down 26.13% YoY), while the FY2025 annual figure was $4.9 million, down 24.13% from the prior year.
• Operating Leases came in at $4.5 million for Q1 2026 at Lexeo Therapeutics, down from $4.9 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $9.0 million in Q4 2022 to a low of $4.5 million in Q1 2026.
• A 5-year average of $6.6 million and a median of $6.6 million in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases dropped 13.49% in 2023 and declined 26.13% in 2026, its largest moves.
• Lexeo Therapeutics' Operating Leases stood at $9.0 million in 2022, then declined by 13.49% to $7.8 million in 2023, then dropped by 17.33% to $6.4 million in 2024, then fell by 24.13% to $4.9 million in 2025, then decreased by 8.44% to $4.5 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $4.5 million, $4.9 million, and $5.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison